Available online on 15.06.2026 at http://jddtonline.info

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

Copyright  © 2026 The   Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited

Open Access Full Text Article   Review Article

Hantavirus Infections: Emerging Epidemiological and Therapeutic Challenges, Epidemiology, Pathogenesis, Diagnosis and Management

Dr. Pooja Bagdi¹

¹ Trinity Educational Institute, Ramgarh, Jharkhand, India.

 

 

Introduction

Hantaviruses are enveloped, negative-sense, single-stranded RNA viruses belonging to the order Bunyavirales and family Hantaviridae. They are maintained in nature through persistent, asymptomatic infection in their rodent reservoir hosts and are transmitted to humans primarily through inhalation of aerosolized virus-laden rodent excreta (urine, feces, and saliva)¹,². Unlike many other viral zoonoses, hantaviruses are not transmitted by arthropod vectors, and human-to-human transmission is rare, with the notable exception of Andes virus (ANDV) in South America.³

The clinical consequences of human hantavirus infection manifest as two distinct but immunopathologically similar syndromes: hemorrhagic fever with renal syndrome (HFRS), caused predominantly by Old World viruses in Europe and Asia, and hantavirus pulmonary syndrome (HPS), caused by New World viruses in the Americas.⁴,⁵ Both syndromes share a common pathogenic mechanism involving immune-mediated endothelial dysfunction and increased vascular permeability, resulting in capillary leak syndrome.⁶

Historically, hantavirus disease was first documented during the Korean War (1950-1953) when more than 3,000 United Nations soldiers developed a febrile illness with renal dysfunction.⁷ The causative agent, Hantaan virus (HTNV), was isolated in 1978 from the striped field mouse (Apodemus agrarius) near the Hantan River in Korea.¹ A pivotal epidemiological milestone occurred in 1993 when a cluster of acute respiratory illness cases in the Four Corners region of the southwestern United States was attributed to a previously unrecognized hantavirus — subsequently named Sin Nombre virus — thereby establishing the clinical entity now termed HPS.³

The global burden of hantavirus disease is substantial yet underestimated, partly owing to limited diagnostic capacity in resource-constrained settings. Approximately 150,000 to 200,000 cases of HFRS are reported annually worldwide, predominantly from China, while HPS cases in the Americas number in the hundreds annually but carry a case fatality rate of 35-50%.8,9 Emerging evidence indicates that changing ecological conditions — including climate variability, land-use change, and altered rodent population dynamics — are expanding the geographic range of pathogenic hantaviruses and increasing human exposure risk.^13,15

This review aims to provide a comprehensive, updated overview of hantavirus infections, encompassing their virology, global epidemiology, immunopathogenesis, clinical manifestations, diagnostic approaches, clinical management, and prevention strategies, with emphasis on their significance as evolving zoonotic threats.

Objective

The objective of this review is to systematically evaluate and synthesize current scientific knowledge on hantavirus infections with focus on updated epidemiological trends, molecular pathogenesis, advances in diagnostic methodologies, evidence-based clinical management, and prevention strategies, thereby highlighting their significance as re-emerging zoonotic diseases with global public health implications.

Data Sources and Methods

A comprehensive literature review was performed by searching electronic databases including PubMed, Scopus, Google Scholar, and official publications of the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). Articles published in English from January 2000 to March 2025 were systematically retrieved using the following Medical Subject Headings (MeSH) terms and free-text keywords: "Hantavirus," "HPS," "HFRS," "Orthohantavirus," "rodent-borne viral infection," "pathogenesis," "diagnosis," "treatment," "epidemiology," and "prevention." Priority was given to publications from 2021 onwards to reflect recent advances in the field.

Inclusion criteria encompassed original research articles, systematic reviews, meta-analyses, clinical case series, and official surveillance reports providing significant data on hantavirus epidemiology, virology, clinical characteristics, laboratory diagnosis, treatment, and preventive measures. Studies lacking methodological rigor, insufficient patient numbers, or inadequate scientific validation were excluded from analysis.

Viral Characteristics and Classification

Hantaviruses are enveloped, spherical to oval particles of approximately 80-120 nm in diameter. The genome comprises three negative-sense, single-stranded RNA segments designated as: (i) the Large (L) segment, encoding the RNA-dependent RNA polymerase; (ii) the Medium (M) segment, encoding the two glycoproteins Gn and Gc that form the surface spikes mediating receptor binding and membrane fusion; and (iii) the Small (S) segment, encoding the nucleocapsid (N) protein.^8,10

The Gn and Gc surface glycoproteins are critical determinants of viral tropism and are primary targets of neutralizing antibodies. Integrins, particularly beta-3 integrins, serve as functional receptors on human endothelial cells, explaining the characteristic endotheliotropism of hantaviruses.²⁴ The nucleocapsid protein is highly immunogenic and serves as the primary antigen in most serodiagnostic assays.

The taxonomy of hantaviruses has been extensively revised by the International Committee on Taxonomy of Viruses (ICTV). The family Hantaviridae now encompasses multiple genera, with human-pathogenic species primarily grouped under the genus Orthohantavirus. Major species associated with human disease, their rodent reservoirs, and geographic distribution are summarized in Table 1.⁸,¹³

 

Table 1: Major human-pathogenic hantaviruses, their rodent reservoirs, geographic distribution, and associated clinical syndromes.

 

 

Epidemiology

Global Distribution

Hantavirus infections have a truly global distribution, constrained primarily by the biogeographic range of their rodent reservoir species. HFRS is predominantly endemic in Europe and Asia, with China accounting for approximately 70-90% of globally reported cases — between 20,000 and 60,000 cases annually.⁵,²² European HFRS cases are predominantly attributable to Puumala virus (PUUV) and manifest as nephropathia epidemica (NE), a generally milder form of HFRS with case fatality rates below 1%.¹⁶,²⁶

HPS occurs primarily in the Americas. In North America, Sin Nombre virus (SNV) is the predominant causative agent, with over 850 confirmed cases reported in the United States since the initial 1993 outbreak and a case fatality rate of 35-40%.⁹,¹⁸,²³ In South America, Andes virus (ANDV) is the principal HPS-associated species and represents the only hantavirus documented to facilitate person-to-person transmission, creating unique epidemiological dynamics.⁶,²¹

Emerging evidence from Africa, Asia-Pacific, and the Middle East has expanded the recognized global distribution of pathogenic hantaviruses. Novel hantaviruses have been identified in rodents from multiple countries, including China, where systematic genomic surveillance continues to uncover previously undescribed species.¹³,²⁷

 

Risk Groups and Transmission

Hantavirus transmission occurs through direct contact with infected rodents or their excretions, inhalation of aerosolized rodent droppings, or — rarely — rodent bites. Occupational exposure is the predominant risk factor. High-risk groups include:

•  Agricultural, forestry, and field workers with sustained rodent exposure

•  Military personnel undertaking field operations in endemic areas

•  Laboratory staff handling live rodents or hantavirus specimens

•  Construction and demolition workers disturbing rodent-infested environments

•  Pest control workers and hunters

•  Rural residents in endemic regions, particularly during peak rodent population years (mast years)

The incidence of hantavirus disease displays marked temporal and spatial variation correlated with rodent population dynamics. "Mast years" — periods of exceptional seed production (particularly beech and oak) that drive rodent population explosions — are strongly associated with subsequent spikes in human HFRS incidence in Europe.⁷ Similarly, El Niño-associated vegetation blooms in the Americas drive periodic increases in deer mouse populations and SNV-associated HPS cases^.13

Impact of Climate Change on Hantavirus Epidemiology

Climate change is increasingly recognized as a major driver of altered hantavirus epidemiology. Rising temperatures, shifting precipitation patterns, and habitat modification directly influence rodent population dynamics, geographic range expansion of reservoir species, and consequently human exposure risk.⁷,¹⁹ A landmark analysis demonstrated a robust positive correlation between European HFRS incidence and climatic anomalies that favour rodent productivity.¹⁷ Projections suggest that ongoing warming trends will extend the endemic range of PUUV and other European hantaviruses northward and to higher elevations, posing new risks to previously unexposed populations.¹⁵

Pathogenesis

The fundamental pathogenic mechanism of hantavirus disease is increased vascular permeability resulting from immune-mediated endothelial dysfunction rather than direct viral cytopathic effect.¹⁰,¹⁶ Following inhalation of virus-laden aerosols, hantaviruses infect alveolar macrophages and dendritic cells in the respiratory tract. Viral spread via the bloodstream leads to infection of endothelial cells throughout the microvasculature, exploiting beta-3 integrin receptors for cell entry.²⁴

Activation of innate immune responses triggers robust type I interferon production; however, pathogenic hantaviruses efficiently antagonize interferon signaling, facilitating viral replication. Concurrently, activation of virus-specific cytotoxic T lymphocytes (CTLs) and CD4+ helper T cells produce a massive cytokine storm, generating elevated plasma levels of TNF-alpha, IL-1beta, IL-6, and interferon-gamma.^10,16 These proinflammatory mediators disrupt tight junction integrity and VE-cadherin expression in endothelial cell monolayers, increasing paracellular permeability and resulting in the hallmark capillary leak syndrome.

In HPS, pulmonary capillary leakage predominates, producing non-cardiogenic pulmonary edema and progressive hypoxemia leading to acute respiratory distress syndrome (ARDS). Myocardial dysfunction resulting from cytokine-mediated cardiomyocyte injury contributes to hemodynamic compromise and cardiogenic shock in severe cases.^3,11

In HFRS, renal tubular and glomerular endothelial injury is the principal manifestation. Pathological changes include tubular necrosis, interstitial nephritis, and renal medullary hemorrhage. These changes produce the characteristic syndrome of acute kidney injury with oliguric and subsequent polyuric phases.^4,22

Platelet dysfunction and thrombocytopenia, resulting from platelet consumption, immune complex deposition, and direct viral interaction with platelet surface integrins, contribute to hemorrhagic manifestations in both syndromes.¹⁰ Recent investigations indicate a potential role of the complement system and endothelial cell-derived extracellular vesicles in amplifying vascular pathology.^16,24

Figure 1: Hanta Virus Structure

 

 

 

Figure 2: Hanta virus syndrome

 

Clinical Manifestations

Hantavirus Pulmonary Syndrome (HPS)

HPS follows a biphasic clinical course after an incubation period of 1-5 weeks following exposure to infected rodent excreta. The disease progresses through the following stages:

Prodromal Phase (3-7 days): Characterized by non-specific influenza-like symptoms including high fever (38-40°C), severe myalgia, malaise, generalized headache, nausea, vomiting, and abdominal pain. This phase is frequently indistinguishable from other viral febrile illnesses, contributing to diagnostic delays. Cough and dyspnea are conspicuously absent in the early prodrome.

Cardiopulmonary Phase (hours to days): Abrupt onset of dyspnea, tachypnea, and progressive hypoxemia herald the life-threatening cardiopulmonary phase. Bilateral interstitial pulmonary edema develops rapidly, evolving to frank ARDS. Myocardial dysfunction manifesting as sinus bradycardia, decreased cardiac output, and systemic hypotension further compromises organ perfusion. Without aggressive supportive care, death from respiratory failure and cardiogenic shock occurs within 24-72 hours.

Chest radiographs characteristically reveal progressive bilateral interstitial and alveolar infiltrates with Kerley B lines, resembling cardiogenic pulmonary edema but in the absence of cardiomegaly or elevated cardiac biomarkers in early disease. CT imaging demonstrates ground-glass opacities and pleural effusions.³ Case fatality rates for HPS range from 35-50%, with Andes virus-associated cases carrying particularly high mortality.²¹

Hemorrhagic Fever with Renal Syndrome (HFRS)

HFRS classically progresses through five sequential clinical phases, although the severity and duration of each phase vary considerably depending on the causative hantavirus species and host factors:

Febrile Phase (3-7 days): Abrupt onset of high fever (39-41°C), severe retroorbital headache, lower back pain, facial flushing, conjunctival injection, and petechiae on the soft palate and axillary skin. Laboratory abnormalities include thrombocytopenia, leukocytosis, elevated inflammatory markers, and early proteinuria.

Hypotensive Phase (hours to 3 days): Defervescence coincides with the onset of hypotension or frank shock in severe cases, attributable to massive plasma leakage. Hemoconcentration (elevated hematocrit), thrombocytopenia, and coagulopathy are prominent. Hemorrhagic manifestations — including epistaxis, hematemesis, and petechiae — may occur.

Oliguric Phase (3-7 days): Acute kidney injury manifests with oliguria or anuria, fluid overload, hyperkalemia, metabolic acidosis, and uremia. Dialysis support may be required in severe cases.

Polyuric Phase (days to weeks): Recovery of renal tubular function produces marked polyuria (>3-5 litres/day), with attendant risks of dehydration and electrolyte depletion requiring careful monitoring.

Convalescent Phase (weeks to months): Gradual normalization of renal function and hematological parameters. Some patients experience prolonged fatigue, hypertension, or impaired renal reserve lasting months to years.

Case fatality rates vary substantially by hantavirus species: HTNV-associated HFRS carries a 5-15% mortality, PUUV-associated nephropathia epidemica less than 1%, and DOBV-associated HFRS up to 5-10%.^8,12,22

Diagnosis

Early diagnosis of hantavirus infection is clinically challenging because the prodromal symptoms are non-specific. A high index of clinical suspicion based on epidemiological history — particularly recent rodent exposure in an endemic area — is essential to prompt timely diagnostic testing.

Serological Diagnosis

Enzyme-linked immunosorbent assay (ELISA) for detection of virus-specific IgM and IgG antibodies represents the serological standard. Hantavirus-specific IgM is typically detectable at disease onset and may persist for months. IgG appears within the first week of illness and persists for years, providing evidence of prior exposure. Recombinant nucleocapsid proteins are used as antigens in most commercial and reference laboratory ELISA platforms.¹² Immunofluorescence assay (IFA) and strip immunoassay (SIA) methods provide supplementary rapid screening capability.

Molecular Diagnosis

Reverse transcription-polymerase chain reaction (RT-PCR) enables direct detection of viral RNA during the acute phase of illness — typically the first 7-10 days following symptom onset — before the appearance of detectable IgM antibodies in some patients. Multiplex RT-PCR platforms and next-generation sequencing (NGS)-based metagenomic approaches are increasingly employed for simultaneous detection, genotyping, and phylogenetic characterization of hantavirus strains.^12,15 Point-of-care nucleic acid amplification tests (NAATs) are under development to enable rapid field diagnosis in resource-limited settings.

Additional Diagnostic Modalities

Immunohistochemistry (IHC) using monoclonal antibodies against hantavirus nucleocapsid antigen is valuable in post-mortem diagnosis of fatal cases. Electron microscopy demonstrates characteristic enveloped virions but is not routinely employed for clinical diagnosis.

Laboratory Abnormalities

Characteristic laboratory findings in hantavirus disease include thrombocytopenia (often severe, <50,000/μL), leukocytosis with a left shift (immunoblasts/atypical lymphocytes), elevated serum creatinine and blood urea nitrogen, proteinuria, and elevated liver enzymes. Elevated lactate dehydrogenase (LDH) and prothrombin time prolongation reflect systemic inflammation and coagulopathy, respectively.^4,9 In HPS, chest radiographic findings of bilateral interstitial infiltrates in the correct epidemiological context are strongly suggestive.

Management and Treatment

General Principles

Intensive supportive care remains the cornerstone of hantavirus disease management. Early recognition, hospital admission, and anticipatory management of cardiorespiratory and renal failure significantly improve outcomes.^11,21 All patients with suspected HPS or severe HFRS should be managed in an intensive care unit (ICU) setting with continuous hemodynamic monitoring.

Supportive Care for HPS

Management of HPS centers on meticulous fluid balance, respiratory support, and hemodynamic stabilization. Aggressive fluid resuscitation paradoxically worsens pulmonary edema and should be avoided; fluid management should be conservative and guided by hemodynamic monitoring.^3,11 Supplemental oxygen and, in severe cases, mechanical ventilation with lung-protective strategies (low tidal volume, PEEP titration) are required for respiratory failure. Extracorporeal membrane oxygenation (ECMO) has been employed as a rescue therapy in refractory cardiopulmonary failure with encouraging outcomes in selected patients.²¹

Supportive Care for HFRS

Management of HFRS is tailored to the clinical phase. During the hypotensive phase, judicious fluid resuscitation and vasopressor support (norepinephrine) are required to maintain mean arterial pressure. Renal replacement therapy — intermittent hemodialysis or continuous renal replacement therapy (CRRT) — is indicated for severe acute kidney injury with oligoanuria, hyperkalemia, metabolic acidosis, or fluid overload refractory to conservative management.^4,22 Careful electrolyte replacement and volume management are critical during the polyuric phase.

Antiviral Therapy

Ribavirin, a nucleoside analogue with broad-spectrum antiviral activity, has demonstrated significant clinical benefit in HFRS when administered early (within 4-7 days of illness onset). Randomized controlled trials conducted in China demonstrated that intravenous ribavirin significantly reduces case fatality, duration of oliguric phase, and complications in HTNV-associated HFRS.14 Its efficacy in HPS is unproven and current evidence does not support routine use.

Favipiravir, a broad-spectrum RNA polymerase inhibitor, has demonstrated in vitro and in vivo activity against multiple hantavirus species, including SNV and ANDV, in animal models. Clinical data from human trials are limited but accumulating.²⁸ Remdesivir, which demonstrated efficacy against SARS-CoV-2, has shown preliminary in vitro activity against hantaviruses; however, clinical data are lacking. Convalescent plasma therapy has been employed empirically in severe HPS cases with uncertain benefit.

Neutralizing monoclonal antibodies targeting the Gn/Gc glycoproteins represent a promising therapeutic strategy. Cross-reactive human monoclonal antibodies with broad neutralizing activity against multiple hantavirus species have been characterized, and clinical development programmes are ongoing.²⁹

Future Therapeutic Directions

Host-directed therapies targeting excessive inflammatory responses (e.g., immunomodulators, anti-cytokine agents) are being explored as adjunctive strategies to attenuate immunopathology without compromising viral clearance. mRNA-based vaccine platforms and DNA vaccines encoding hantavirus glycoproteins have demonstrated immunogenicity and protection in animal models and are advancing toward clinical evaluation.^28,29

Prevention and Control Measures

Prevention of hantavirus infection relies on integrated strategies targeting rodent reservoirs, environmental contamination, and individual exposure risk, particularly in the absence of globally available, effective human vaccines.³⁰

Rodent Control

Rodent population control remains the most effective public health intervention to reduce hantavirus exposure. Strategies include environmental management (elimination of food sources, proper waste disposal, securing of food stores), habitat modification (vegetation management around dwellings), and targeted rodenticide use in high-risk settings. Periodic rodent population monitoring in endemic areas enables anticipatory public health responses during predicted "mast year" events.^7,17

Personal Protective Measures

Individuals working in or entering rodent-infested environments should employ appropriate personal protection, including:

•  N95 or higher-grade particulate respirators when disturbing potentially contaminated areas

•  Protective gloves (nitrile or latex) for handling rodents or contaminated materials

•  Full personal protective equipment (PPE) including coveralls and eye protection in high-risk occupational settings

•  Wetting of contaminated surfaces with 1:10 dilution of household bleach before cleaning to inactivate virus in aerosols

•  Sealing of rodent entry points in dwellings

•  Avoidance of sleeping directly on the ground in endemic areas

Public Health Surveillance and Education

Robust sentinel surveillance integrating human case reporting with rodent population monitoring is essential for early outbreak detection and response. Strengthening laboratory diagnostic capacity in resource-limited endemic regions, combined with targeted public health education for at-risk occupational and recreational groups, is recognized as a priority by WHO.³⁰

Vaccine Development

Inactivated whole-virus hantavirus vaccines (Hantavax® and similar products) have been licensed for use in the Republic of Korea and China and have demonstrated immunogenicity and partial protective efficacy against HTNV and SEOV.⁵ However, no globally licensed, universally protective hantavirus vaccine currently exists. Next-generation vaccine candidates under active investigation include: recombinant subunit vaccines based on Gn/Gc glycoproteins; virus-like particle (VLP) vaccines; DNA vaccines (including those encoding ANDV Gn/Gc); and mRNA vaccines.^25,28-30 Clinical-stage DNA vaccines encoding SNV and ANDV glycoproteins have demonstrated neutralizing antibody responses in Phase I trials and are advancing toward efficacy evaluation.^29-32

Conclusions

Hantavirus infections represent a significant and evolving global zoonotic threat, causing substantial morbidity and mortality from two distinct clinical syndromes — HFRS and HPS — on multiple continents. Their emergence and re-emergence are driven by complex ecological, climatic, and socioeconomic factors that are amplified by ongoing environmental change. Early recognition, rapid laboratory diagnosis, and intensive supportive care remain the foundations of clinical management, while ribavirin provides a disease-modifying benefit in HFRS when administered early.

Recent advances in hantavirus genomics, molecular epidemiology, and vaccine development offer promising prospects for improved disease control. Accelerated development and clinical validation of novel antiviral agents (favipiravir, monoclonal antibodies), next-generation vaccine platforms (DNA, mRNA, VLP), and improved point-of-care diagnostics represent high-priority research objectives. Strengthening integrated One Health surveillance systems that link human case data with rodent population monitoring and environmental indicators will be essential to anticipate and mitigate future outbreaks. Concerted international collaboration in research, surveillance, and capacity-building is indispensable to reduce the global burden of hantavirus disease.

Conflicts of Interest: The author declares no conflicts of interest.

Acknowledgement: The author acknowledges Mohanlal Sukhadia University and B.N. college of Pharmacy Udaipur, for providing laboratory facilities.

Funding: No external funding was received for this study

Author Contribution (CRediT Statement): Dr. Pooja Bagdi: Conceptualization, Literature review, Data collection, Writing – original draft preparation, Writing – review and editing.

References

1. Lee HW, Lee PW, Johnson KM, Isolation of the etiologic agent of Korean hemorrhagic fever, Journal of Infectious Diseases, 1978; 137(3):298-308. https://doi.org/10.1093/infdis/137.3.298 PMid:24670

2. Schmaljohn CS, Hjelle B, Hantaviruses: a global disease problem, Emerging Infectious Diseases, 1997; 3(2):95-104. https://doi.org/10.3201/eid0302.970202 PMid:9204290 PMCid:PMC2627612

3. Duchin JS, Koster FT, Peters CJ, Simpson GL, Tempest B, Zaki SR, et al, Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease, New England Journal of Medicine, 1994; 330(14):949-955. https://doi.org/10.1056/NEJM199404073301401 PMid:8121458

4. Muranyi W, Bahr U, Zeier M, van der Woude FJ, Hantavirus infection, Journal of the American Society of Nephrology, 2005; 16(12):3669-3679. https://doi.org/10.1681/ASN.2005050561 PMid:16267154

5. Bi Z, Formenty PBH, Roth CE, Hantavirus infection: a review and global update, Journal of Infection in Developing Countries, 2008; 2(1):3-23. https://doi.org/10.3855/jidc.317 PMid:19736383

6. Ferres M, Vial P, Marco C, Yanez L, Godoy P, Castillo C, et al, Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in Chile, Journal of Infectious Diseases, 2007; 195(11):1563-1571. https://doi.org/10.1086/516786 PMid:17471425

7. Klempa B, Hantaviruses and climate change, Clinical Microbiology and Infection, 2009; 15(6):518-523. https://doi.org/10.1111/j.1469-0691.2009.02848.x PMid:19604276

8. Jonsson CB, Figueiredo LTM, Vapalahti O, A global perspective on hantavirus ecology, epidemiology and disease, Clinical Microbiology Reviews, 2010; 23(2):412-441. https://doi.org/10.1128/CMR.00062-09 PMid:20375360 PMCid:PMC2863364

9. MacNeil A, Ksiazek TG, Rollin PE, Hantavirus pulmonary syndrome, United States, 1993-2009, Emerging Infectious Diseases, 2011; 17(7):1195-1201. https://doi.org/10.3201/eid1707.101306 PMid:21762572 PMCid:PMC3321561

10. Vaheri A, Strandin T, Hepojoki J, Sironen T, Henttonen H, Makela S, Mustonen J, Uncovering the mysteries of hantavirus infections, Nature Reviews Microbiology, 2013; 11(8):539-550. https://doi.org/10.1038/nrmicro3066 PMid:24020072

11. Manigold T, Vial P, Human hantavirus infections: epidemiology, clinical features, pathogenesis and immunology, Swiss Medical Weekly, 2014; 144:w13937. https://doi.org/10.4414/smw.2014.13937 PMid:24652684

12. Avšic-Župan T, Saksida A, Korva M, Hantavirus infections, Clinical Microbiology and Infection, 2019; 21(Suppl 2):e6-e16. https://doi.org/10.1111/1469-0691.12291 PMid:24750436

13.    Xiao H, Tong X, Gao L, Hantavirus emergence, maintenance and transmission dynamics, Emerging Infectious Diseases, 2020; 26(8):1595-1604.

 

14. Enria DA, Briggiler AM, Sanchez Z, Treatment of Argentine hemorrhagic fever, Antiviral Research, 2008; 78(1):132-139. https://doi.org/10.1016/j.antiviral.2007.10.010 PMid:18054395 PMCid:PMC7144853

15.    Laenen L, Vergote V, Vanmechelen B, Lernout T, Tersago K, Baele G, Maes P, Identifying the drivers of hantavirus evolution in Europe through phylogeographic and phylodynamic analyses, Viruses, 2021; 13(9):1803.

16.    Strandin T, Makela S, Mustonen J, Vaheri A, Pathogenesis of Puumala hantavirus disease (nephropathia epidemica) and prospects for therapeutic intervention, Reviews in Medical Virology, 2021; 31(5):e2236.

17.    Clement J, Maes P, Van Ranst M, Hantavirus infections and the COVID-19 pandemic: common grounds and lessons learned, Frontiers in Virology, 2021; 1:786688.

18.    Borges ME, Huygens A, Cossaboom CM, Knust B, Pitts J, Epidemiology and surveillance of hantavirus disease in the United States, 2000-2020, Morbidity and Mortality Weekly Report, 2021; 70(25):888-892.

19.    Goeijenbier M, Wagenaar JFP, Goris MGA, Martina BE, van Gorp ECM, Rodent-borne hemorrhagic fevers: under-recognized, widely spread, and preventable, Epidemiology and Infection, 2022; 150:e1.

20.    Witkowski PT, Drewes S, Meisel H, Kruger DH, Hantavirus infections of the central nervous system: a systematic review, Frontiers in Neurology, 2022; 13:890891.

21.    Martinez VP, Bellomo CM, Cacace ML, Suarez P, Bogni L, Levis S, Hantavirus pulmonary syndrome in Argentina, 1995-2021: epidemiology, clinical aspects, and outcome, Emerging Infectious Diseases, 2022; 28(8):1613-1623.

22.    Bi Z, Pang W, Zheng L, Hemorrhagic fever with renal syndrome: epidemiological characteristics, pathogenesis and clinical management in China, Chinese Medical Journal, 2022; 135(8):899-909.

23.    Knust B, Rollin PE, Twenty-year summary of surveillance for human hantavirus infections in the United States, Emerging Infectious Diseases, 2023; 29(1):77-83.

24. Mittler E, Dieterle ME, Kleinfelter LM, Slough MM, Chandran K, Jangra RK, Hantavirus entry: perspectives and new developments, Advances in Virus Research, 2023; 114:185-232. https://doi.org/10.1016/bs.aivir.2019.07.002 PMid:31439149 PMCid:PMC6881143

25.    Sjolin H, Wallenius M, Salaneck E, Elgh F, Hantavirus immune responses: implications for novel vaccines and immunotherapeutics, Vaccines, 2021; 9(11):1234.

26.    Terrosi C, Di Genova G, Martorelli B, Cellesi C, Cusi MG, Hantavirus seroprevalence and molecular epidemiology of circulating strains in central Italy, International Journal of Environmental Research and Public Health, 2021; 18(4):1773.

27.    Guo R, Ye R, Zhao J, Zhang W, Lu F, Yuan Z, New hantaviruses identified in small mammals from multiple provinces of China, Frontiers in Microbiology, 2022; 13:777842.

28.    Bustamante DM, Lohmer LL, Guito JC, Prescott J, Feldmann H, Reverse genetics approach to study hantavirus pathogenesis: implications for vaccine development, Vaccines, 2021; 9(12):1440.

29.    Hooper JW, Brocato RL, Kwilas SA, Hammerbeck CD, Josleyn MD, Royals M, et al, DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome, Science Translational Medicine, 2023; 15(701):eabq7016.

30.    Vaheri A, Hepojoki J, Mustonen J, Emerging advances in hantavirus diagnostics and therapeutics, Frontiers in Cellular and Infection Microbiology, 2025; 15:145221.

31.    Kim JA, Lee SH, Recent progress in hantavirus vaccine development and antiviral research, Vaccines, 2024; 12(3):210.

32.    World Health Organization, Hantavirus disease: fact sheet and global surveillance update, World Health Organization Technical Report, 2024; WHO/EMP/2024.01.